This Forum will be one of the stars of the show as we have attracted high-profile regulators and senior representatives from industry
Basel, Switzerland (Vocus) February 5, 2008
The Drug Information Association (DIA) will celebrate the 20th Anniversary of the EuroMeeting in Barcelona, Spain, from March 3-5, 2008.
The 20th Annual EuroMeeting will feature presentations by more than 350 speakers, 20 pre-conference tutorials, student and professional poster sessions, over 250 exhibitors and exciting networking events. However, this year's event will look a bit different from years past.
"The 2008 EuroMeeting will build on the past successes and strengths. We have listened to what delegates want and to what is important to industry professionals today," says Truus Janse-de Hoog, EuroMeeting Co-chair. "In response, we have introduced innovations to the format of the event, while maintaining the traditional EuroMeeting quality standards, creating even greater value for attendees."
This year's event is divided into 11 themes, rather than the traditional tracks, with up to nine sessions in each theme. According to Brigitte Franke-Bray, Director, DIA Europe, it is important that attendees embrace the entire multidisciplinary concept of the meeting. "Drug development these days does not operate in an isolated environment. You are part of a team," she explains. "We wanted the EuroMeeting to move towards a more 'team-facing' structure."
- Communication on Health and Medicines: Challenges and Opportunities
- Health Economics and Pharmaceutical Policies
- The Combination of Drugs with Medical Devices: A Chance for the Pharmaceutical Industry
- Clinical Research: The Critical Success Factor in Drug Development
- How to Enhance Drug Development
- The Future of Treatment
- Impact of Electronic Acquisition and Exchange on Drug Development
- Consumer Health - A Diverse and Challenging Sector
- Managing Risk Through Effective Systems
- The Future of Regulation
- Globalisation of Drug Development
This year's meeting will showcase several hot topic sessions, including:
- Advanced Therapies in the EU - Today and Tomorrow
- Communication on Risk and Safety Issues of Medicines
- First in Man Trials - Impact of New Guidelines
- National and/or CHMP Advice: A Place for Each?
- Surrogate Endpoints: Balancing the Objectives of Patients
Industry and Regulators
- Use of Electronic Health Records in Clinical Research
- Eudra Databases
- Pharmacogenomics--Present and Future Directions
"How Far Have We Come In Establishing A Single Market? (Monday, March 3) will be held as a high-level panel discussion to explore the future pharmaceutical regulation in the European Union. In July 2007, the European Commission encouraged all stakeholders to "Have Your Say" in a consultation exercise involving a series of wide-ranging questions, including market access and regulatory approval procedures. Following this public debate, the Commission intends to address a communication to the Council of the European Union and to the European Parliament on the future of the EU single market in pharmaceuticals for human use, outlining its vision and strategy for the sector. Email your questions in advance to dermot.ryan @ diaeurope.org.
Finding solutions to industry challenges requires comprehensive approaches that draw on the expertise of international and multidisciplinary thought leaders from academia, regulatory agencies, and private industries.
European Regulatory Forum
The European Regulatory Forum will provide an update on the work of the CHMP and Scientific Advisory Groups (SAGs), the Co-ordination group CMD(h), the work of the Paediatric Committee and the assessment of paediatric data, new pharmacovigilance activities, Quality and Safety Working parties and the hot topics in telematics. "This Forum will be one of the stars of the show as we have attracted high-profile regulators and senior representatives from industry," notes Beat Widler, EuroMeeting Co-chair.
Spanish Satellite Meeting
The Spanish Agency of Medicines and Medical Devices will examine the activities and aims of the Spanish Agency and the challenges for the coming years.
The Pharmaceuticals and Medical Devices Agency (PMDA) will explain the current PMDA/Japanese drug regulatory environment and present PMDA perspectives for successful global drug development including Japan.
For more information, contact Dermot Ryan at +41 61 225 5132 or Dermot.Ryan @ diaeurope.org. Media interested in attending the event or arranging for pre- or post-event interviews should contact Joe Krasowski at +1-215-293-5812 or Joe.Krasowski @ diahome.org. For a complete list of exhibiting companies, click here.
About the Drug Information Association (DIA)
The Drug Information Association (DIA) serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland and Tokyo, Japan, the Association is led by its volunteer-based board of directors and executive management team. For more information, visit http://www.diahome.org or call 215-442-6100.